MEMANT-3310 is under clinical development by Antabio and currently in Phase I for Enterobacteriaceae Infections. According to GlobalData, Phase I drugs for Enterobacteriaceae Infections have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MEMANT-3310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEMANT-3310 overview
MEMANT-3310 is under development for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections and hospital acquired infections caused by Gram negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant A. baumannii (CRAB). It is a combination of meropenem and ANT-3310. It is administered through intravenous route. ANT-3310 acts by targeting serine beta-lactamases and meropenem acts by targeting penicillin binding protein (PBP).
Antabio overview
Antabio is a biopharmaceutical company. It develops novel antibacterials targeting drug-resistant pathogens. The company’s pipeline products comprise Metallo Beta-Lactamases inhibitors, Pseudomonas Biofilms inhibitors and others. It uses in vitro technologies and bacterial disease know-how for the development of next generation antibacterial drugs targeting severe and difficult-to-treat infections caused by multi-drug resistant gram-negative pathogens. Antabio’s therapies provide treatment of medical needs of the antibacterial space and to address infections caused by pathogens. It also acquires additional assets on gram-negative antibiotic resistant therapies. Antabio is headquartered in Labege, France.
For a complete picture of MEMANT-3310’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
